Arctoris and SpiroChem Enter into Strategic Partnership to Accelerate Drug Discovery

Partnership creates integrated solution and aims to streamline biology and chemistry drug discovery processes for biotechnology and pharmaceutical companies worldwide

Oxford, UK, Boston, USA and Basel, Switzerland. 03 October 2024 Arctoris, a leading contract research organisation (CRO) advancing drug discovery experimentation through its unique automated laboratory and data science platform, UlyssesⓇ, today announced it has entered into a joint partnership with SpiroChem AG. 

The partnership combines Arctoris’ cutting-edge automated biology capabilities with SpiroChem’s world-class medicinal and synthetic chemistry platforms including photochemistry, electrochemistry, flow chemistry, and parallel solid-phase synthesis. This unique combination of biological and chemistry expertise provides a novel end-to-end drug discovery solution that:

• Accelerates timelines from hit identification to candidate selection
• Enhances data quality and reproducibility through automation
• Provides access to diverse chemical space and novel scaffolds
• Offers complete project support, scientific consulting, and logistics management
• Comprises flexible engagement models tailored to specific project needs

Arctoris, founded in 2016 and headquartered in Oxford, UK, has developed the Ulysses platform, which combines robotics, automation, and artificial intelligence to generate high-quality, reproducible data for drug discovery. SpiroChem, established in 2011 as a spin-off from ETH Zürich, is a global leader in discovery chemistry providing proprietary libraries and advanced chemistry solutions.

Tom Fleming, CEO of Arctoris, commented: “By joining forces with SpiroChem, we’re creating a powerhouse in drug discovery with the potential to significantly accelerate their drug discovery timelines. The partnership combines our automated biology platform with SpiroChem’s innovative chemistry platforms to offer biotech and pharma organisations a highly differentiated integrated cutting-edge solution.”

Thomas Fessard, CEO of SpiroChem, commented: “Our partnership with Arctoris marks an important milestone, extending our chemistry expertise into a fully integrated discovery platform. With this joint offering, we are setting a new benchmark for innovation and efficiency in the pursuit of novel therapeutics

Media Contacts:

media@arctoris.com

contact@spirochem.com

About Arctoris Ltd. www.arctoris.com 

Arctoris is a tech-enabled drug discovery company headquartered in Oxford, UK, with a U.S. presence in Boston. By combining scientific expertise with advanced lab automation, Arctoris brings confidence and speed to small-molecule drug discovery for biotech and pharma companies around the globe. Arctoris’ unique platform, Ulysses®, enables rapid generation of the highest-quality data from idea to IND and beyond.

About SpiroChem AG

SpiroChem is a pioneering research partner providing innovative solutions across the drug discovery and process R&D chemistry value chain. Its world-class team, equipped with deep collective knowledge and the most advanced technology platforms, offers expertise that accelerates research and reaches regulatory milestones for both complex and simple molecules. Through innovative problem-solving, clear communication and transparency, SpiroChem offers its clients ‘the best chance of being successful’. Founded in 2011 and headquartered in Basel, Switzerland, SpiroChem has a strong presence near key life science hubs, with a second R&D site in Montreal, Canada.